ID Biomedical at strong buy by JMP

ID Biomedical Corp. was rated a strong buy with a C$31.00 price target by JMP Securities analyst Adam Cutler, who noted the company's Fluviral has about a 75% market share in Canada and will likely be approved in the first half of 2006. ID Biomedical shares closed Friday up C$2.45, or 10.32%, at C$26.20 on volume of 150,501 shares versus a three-month trailing average of 46,952 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.